Vera Therapeutics director receives 17,084 stock options
Vera Therapeutics director Patrick G. Enright received a stock option grant for 17,084 shares of Class A common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Vera Therapeutics director Patrick G. Enright received a stock option grant for 17,084 shares of Class A common stock. The option has an exercise price of $34.35 per share and expires on May 20, 2036. All 17,084 options were held directly after the grant.
The footnote states the option will vest in full on the earlier of the first anniversary of the grant date or the date of Vera Therapeutics' 2027 annual stockholder meeting, subject to continuous service. It will also vest in full upon a change in control if his service continues through that date.
Insider Trade Summary
Grant/Award: 17,084 shares
Grant/Award
1 txn
Insider
ENRIGHT PATRICK G
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 17,084 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 17,084 contracts (Direct)
Footnotes (1)
- F1. The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control.
Key Figures
Option shares granted: 17,084 shares
Exercise price: $34.35 per share
Shares underlying options: 17,084 shares
+2 more
5 metrics
Option shares granted
17,084 shares
Stock option grant to director Patrick G. Enright
Exercise price
$34.35 per share
Strike price for the granted stock options
Shares underlying options
17,084 shares
Class A common stock underlying the option
Expiration date
May 20, 2036
Option expiration for the grant
Post-grant option holdings
17,084 derivative securities
Total options held following the transaction
Key Terms
Stock Option (right to buy), Class A Common Stock, exercise price, change in control, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
Class A Common Stock financial
"underlying_security_title: Class A Common Stock"
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
exercise price financial
"conversion_or_exercise_price: 34.3500"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
change in control financial
"shares will vest in full upon a change in control"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
continuous service financial
"subject to the Reporting Person's continuous service through such vesting date"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Patrick G. Enright report in this Vera Therapeutics (VERA) Form 4?
Patrick G. Enright reported receiving a grant of stock options for 17,084 shares of Vera Therapeutics Class A common stock. The options are a compensation-related award, not an open-market purchase or sale, and are held directly following the transaction.
What is the exercise price of the Vera Therapeutics (VERA) options granted to Patrick G. Enright?
The stock options granted to Patrick G. Enright have an exercise price of $34.35 per share. This means he can purchase Vera Therapeutics Class A common stock at $34.35 per share once the options vest, subject to the vesting conditions described.
When do Patrick G. Enright’s Vera Therapeutics (VERA) options vest?
The options vest in full on the earlier of the first anniversary of the grant date or Vera Therapeutics’ 2027 annual stockholder meeting. Vesting requires Patrick G. Enright’s continuous service, with full vesting also triggered upon a change in control if he remains in service.
When do Patrick G. Enright’s Vera Therapeutics (VERA) stock options expire?
The stock options granted to Patrick G. Enright expire on May 20, 2036. If not exercised by that expiration date, the right to purchase Vera Therapeutics Class A common stock at the $34.35 exercise price will lapse under the terms disclosed.
Is Patrick G. Enright’s Vera Therapeutics (VERA) Form 4 transaction a market buy or sell?
The filing shows a grant or award acquisition of stock options, not a market buy or sell. The transaction code is “A,” indicating a compensation-related award with no open-market purchase or sale of Vera Therapeutics common shares.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates